Data investigation
More Effect Without More Side Effects
Almost every result in this field trades benefit against harm. Adding cagrilintide to semaglutide produced 6.5 percentage points more weight loss with gut side effects at 53% against 51%.
Almost every result on this register trades benefit against harm. A trial comparing cagrilintide–semaglutide against semaglutide alone found 6.5 percentage points more weight loss with gastrointestinal side effects at 53% against 51%.[1] That is close to free, which almost nothing in this field is. It is not entirely free, though, and the reason is in the discontinuation column.
Why the comparator matters
Most trials of a new combination test it against placebo, which answers a question nobody has. Someone already taking semaglutide wants to know whether adding a second agent does anything. This trial randomized 331 adults in Japan and Taiwan to cagrilintide–semaglutide or to semaglutide by itself, for 68 weeks.
| Cagrilintide–semaglutide | Semaglutide alone | |
|---|---|---|
| Weight change | −18.4% (SE 0.7) | −11.9% (0.7) |
| Difference | −6.5 percentage points (95% CI −8.4 to −4.6), p<0.0001 | — |
| Any adverse event | 87% | 84% |
| Gastrointestinal disorders | 53% | 51% |
| Discontinued | 10% | 6% |
Cagrilintide is an amylin analog, so it works through a different hormone system from GLP-1 and acts on satiety by another route. That is why adding it is not the same as raising the semaglutide dose, and it is the likely reason the side-effect profile did not simply scale. What it does on its own is covered in cagrilintide: what the evidence shows, and the other amylin drugs in eloralintide and petrelintide.
The pattern this breaks
The rule still holds for raising a dose, where more of the same drug means more of the same effects. Adding a different mechanism is a different operation, and this result suggests it does not carry the same cost.
For where the general pattern comes from, see what 262 trials say together; for the clearest examples of it, what tripling the dose buys and the top dose keeps not being worth it.
The column that shows it is not free
The difference between how many people have an event and how many quit runs through this whole literature, and the two point in different directions surprisingly often. An event rate counts occurrences. A discontinuation rate counts the ones that mattered enough to end treatment, which is the only measure that captures severity, duration and how it felt.
In short, the combination buys substantially more weight loss for a modest tolerability cost, and that cost is real and shows up in the place that matters most.
Who was studied
- Japan and Taiwan, which makes this one of the few trials in this field conducted outside Europe and North America.
- 68% men, the opposite of this field’s usual skew, where trials over-recruit women.
- Around a quarter had type 2 diabetes, which lowers weight response across this class.
- Sixty-eight weeks, with no cardiovascular or other outcome data.
One death occurred, in the semaglutide arm, judged unrelated to treatment by the investigator.
For what “superior” means when this combination is compared in its other trials, see CagriSema: superior by how much.
Frequently Asked Questions
References
- 1.Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial The Lancet Diabetes & Endocrinology. 2026. PMID: 42009015.
Compare the sellers
Related research
One Injection Instead of Twenty-Eight
Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.
6 min read
What Tripling the Dose Buys
A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.
7 min read
Newer Is Not Stronger
Survodutide has a new mechanism and phase 3 results in the NEJM. It produced 13.0% weight loss at 76 weeks, and its higher dose caused gut side effects in nearly nine of ten participants while losing only 0.8 points more weight than the lower dose.
7 min read
What 262 Trials Say Together
262 trials, 99,791 people, 19 drugs, every result graded. Three of its findings cut against how this field is described, starting with the fact that the drug with the mortality evidence is not the one that takes off the most weight.
9 min read
The Genetics Are Real, and Small
A genome-wide study found genetic predictors of GLP-1 weight loss and side effects, at overwhelming significance. The efficacy effect is about three-quarters of a kilogram per copy.
8 min read
When the Appetite Center Is Damaged
For people whose obesity follows damage to the brain's appetite center, almost nothing works. A study of 116 patients found modest average weight loss and something more important: 8% hospitalized for hormonal decompensation.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →